Discriminating cross-reactivity in polyclonal IgG1 responses against SARS-CoV-2 variants of concern.
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
15 10 2022
15 10 2022
Historique:
received:
22
03
2022
accepted:
07
10
2022
entrez:
15
10
2022
pubmed:
16
10
2022
medline:
19
10
2022
Statut:
epublish
Résumé
Existing assays to measure antibody cross-reactivity against different SARS-CoV-2 spike (S) protein variants lack the discriminatory power to provide insights at the level of individual clones. Using a mass spectrometry-based approach we are able to monitor individual donors' IgG1 clonal responses following a SARS-CoV-2 infection. We monitor the plasma clonal IgG1 profiles of 8 donors who had experienced an infection by either the wild type Wuhan Hu-1 virus or one of 3 VOCs (Alpha, Beta and Gamma). In these donors we chart the full plasma IgG1 repertoires as well as the IgG1 repertoires targeting the SARS-CoV-2 spike protein trimer VOC antigens. The plasma of each donor contains numerous anti-spike IgG1 antibodies, accounting for <0.1% up to almost 10% of all IgG1s. Some of these antibodies are VOC-specific whereas others do recognize multiple or even all VOCs. We show that in these polyclonal responses, each clone exhibits a distinct cross-reactivity and also distinct virus neutralization capacity. These observations support the need for a more personalized look at the antibody clonal responses to infectious diseases.
Identifiants
pubmed: 36243713
doi: 10.1038/s41467-022-33899-1
pii: 10.1038/s41467-022-33899-1
pmc: PMC9568977
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Antigens, Viral
0
Immunoglobulin G
0
Spike Glycoprotein, Coronavirus
0
spike protein, SARS-CoV-2
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
6103Informations de copyright
© 2022. The Author(s).
Références
Clin Infect Dis. 2020 Nov 19;71(16):2027-2034
pubmed: 32221519
J Autoimmun. 2021 Mar;118:102596
pubmed: 33540371
Cell Rep. 2020 Jun 2;31(9):107725
pubmed: 32426212
Nat Commun. 2018 Jun 27;9(1):2493
pubmed: 29950687
Elife. 2021 Nov 23;10:
pubmed: 34812143
Nature. 2020 Aug;584(7819):115-119
pubmed: 32454513
ILAR J. 2005;46(3):258-68
pubmed: 15953833
Nat Biotechnol. 2014 Feb;32(2):158-68
pubmed: 24441474
Sci Rep. 2021 Sep 3;11(1):17642
pubmed: 34480056
Science. 2020 Aug 7;369(6504):643-650
pubmed: 32540902
Cell Rep. 2021 Feb 2;34(5):108699
pubmed: 33485405
Sci Transl Med. 2021 Jun 2;13(596):
pubmed: 33979301
Science. 2021 Aug 13;373(6556):818-823
pubmed: 34016740
Signal Transduct Target Ther. 2021 Sep 24;6(1):346
pubmed: 34561414
Science. 2020 Dec 11;370(6522):1339-1343
pubmed: 33159009
Cell Syst. 2021 Dec 15;12(12):1131-1143.e5
pubmed: 34613904
J Exp Med. 2020 Nov 2;217(11):
pubmed: 32692348
Front Immunol. 2020 Sep 30;11:582010
pubmed: 33117392
Nat Rev Microbiol. 2021 Jul;19(7):409-424
pubmed: 34075212
Microbiol Spectr. 2021 Oct 31;9(2):e0073121
pubmed: 34523985
Proc Natl Acad Sci U S A. 2021 Oct 1;118(42):
pubmed: 34599091
Int J Mol Sci. 2022 May 27;23(11):
pubmed: 35682724
Cell Mol Immunol. 2021 Jul;18(7):1826-1828
pubmed: 34059791
Nat Rev Immunol. 2020 Oct;20(10):581-582
pubmed: 32839569
Sci Adv. 2021 Sep 03;7(36):eabj5365
pubmed: 34516917
Clin Infect Dis. 2020 Jul 28;71(15):778-785
pubmed: 32198501
mBio. 2020 Oct 16;11(5):
pubmed: 33067385
J Virol Methods. 2021 Feb;288:114025
pubmed: 33227340
Immunity. 2020 Aug 18;53(2):442-455.e4
pubmed: 32668194
Commun Biol. 2021 Nov 22;4(1):1317
pubmed: 34811480
ACS Cent Sci. 2021 Nov 24;7(11):1863-1873
pubmed: 34845440
Viruses. 2021 Jun 22;13(7):
pubmed: 34206453